Mary Kay Challenges Global Youth to Address SDG 14: Life Below Water in Third Annual Network for Teaching Entrepreneurship World Series of Innovation Challenge
15.9.2022 18:05:00 EEST | Business Wire | Press release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announces its third annual World Series of Innovation (WSI) challenge in partnership with Network for Teaching Entrepreneurship (NFTE). The global competition invites young people ages 13-24 to put their critical thinking skills to the test and get involved in solving some of the biggest challenges humanity faces today to advance the UN Sustainable Development Goals (SDGs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005847/en/
Network for Teaching Entrepreneurship an international nonprofit organization providing entrepreneurship training and educational programs to middle and high school students, college students, and adults (Graphic: Network for Teaching Entrepreneurship)
Mary Kay’s WSI challenge kicks off September 15 in conjunction with World Clean Up Day. The Mary Kay challenge encourages young entrepreneurs to submit innovative solutions to address UN SDG 14: Life Below Water. Specifically, students are challenged to design a solution to further the conservation and/or protection of the world’s marine ecosystems and coastal communities.
“All life on Earth began in and depends on our oceans. Water is the most valuable resource on our planet, and it’s essential that we not only respect it, but do our part to protect it,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “The next generation of global thinkers and leaders are already addressing these critical areas of concern and spearheading conservation efforts. We are excited to see how the world’s youth can help to advance ecosystems and biodiversity conservation globally.”
In its first year partnering with the NFTE World Series of Innovation in 2020, Mary Kay sponsored a WSI challenge for UN SDG 12: Responsible Consumption and Production. Young entrepreneurs were encouraged to design a product, service or initiative that promoted the reuse or upcycling of textiles. In 2021, Mary Kay sponsored its second WSI challenge to address UN SDG 5: Gender Equality. Students were tasked with developing programs to promote workplace equality and ensure equal access to economic opportunity for women and girls.
“Mary Kay Global Oceans Conservations Challenge dares our young WSI competitors to think big about water quality,” said Dr. J.D. LaRock, President and CEO of NFTE. “In classrooms, students learn that water is fundamental to a healthy ecosystem. Through experiences like WSI, however, they become empowered to sustain that resource. They can ideate ways to look after marine life, safeguard oceans, secure affordable access to clean drinking water, protect water resources from pollution, address overconsumption, or otherwise help preserve our ecosystem for generations to come. That’s powerful.”
NFTE is a global educational non-profit focused on bringing the power of entrepreneurship to low-income communities. Since its founding more than 35 years ago, NFTE has trained thousands of teachers and educated well over a million young people worldwide. Every fall, NFTE launches a new set of challenges for the WSI competition and invites corporate sponsors to address the UN SDGs. The 2022 NFTE World Series of Innovation is presented by Citi Foundation and features challenges sponsored by Mary Kay Inc., MetLife Foundation, Mastercard, Bank of the West, Link, Maxar, Ernst & Young, LLP (EY), ServiceNow and Zuora. The top three winners will be announced in early 2023.
For more information on the World Series of Innovation and all challenges, visit https://innovation.nfte.com/.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005847/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom